Seventy two subjects with OCD were compared with 18 normal healthy volunteers on multiple neuroendocrine responses to clonidine. Significant heterogeneity in OCD was observed in responses of growth hormone. There was also significant disturbances in Cortisol and ACTH release. An interactional model for noradrenergic and serotonergic dysfunction in OCD is discussed. One of the strategies commonly used in studying noradrenergic function in depression is the neuroendocrine response to clonidine (Siever and Uhde, 1984). The measure moat commonly used in the growth hormone response. However it is now recognised that there is alpha-2 adrenergic involvement in the control of several other hormones, specifically Cortisol, ACTH and perhaps prolactin (Bennett, and Whitehead, 1983) and consistent changes in these parameters have been reported in nor-
Seventy two subjects with OCD were compared with 18 normal healthy volunteers on multiple neuroendocrine responses to clonidine. Significant heterogeneity in OCD was observed in responses of growth hormone. There was also significant disturbances in Cortisol and ACTH release. An interactional model for noradrenergic and serotonergic dysfunction in OCD is discussed. (Khanna, 1988; 1992 and Zohar and Insel, 1987) . However it is widely accepted that the serotonergic model does not explain all abnormalities in OCD as treatment nonresponders are recognised. The most extreme position is probably adopted by Marks (1987) who believes that the effect of serotonin uptake inhibitors is only in the associated depression and has no effect on the obsessive compulsive state per se. One of the strategies commonly used in studying noradrenergic function in depression is the neuroendocrine response to clonidine (Siever and Uhde, 1984). The measure moat commonly used in the growth hormone response. However it is now recognised that there is alpha-2 adrenergic involvement in the control of several other hormones, specifically Cortisol, ACTH and perhaps prolactin (Bennett, and Whitehead, 1983) and consistent changes in these parameters have been reported in nor-mals (Khanna et al., 1990) . There have been recent reports of the usage of such strategies as marker of the noradrenergic dysfunctional statein melancholic depression (Amsterdam et al., 1989) . The usage of multiple neuroendocrine marker in response to alpha-2 agonists like clonidine helps assessing both pre and postsynaptic noradrenergic functions.
Obsessive Compulsive Disorder (OCD)
The current study is an attempt at exploring noradrenergic function in OCD using multiple neuroendocrine responses to clonidine and determining whether there are different subgroups based on noradrenergic function in OCD.
METHODOLOGY

PATIENTS
The patients included in this study met DSM III criteria for OCD (American Psychiatric Association, 1980) . Patients characteristics are given in Table 2 . Subjects who had Hamilton Depression Scores (Hamilton, 1960) greater than 11 were excluded from the study. All subjects gave written consent to participate in this study: None of the patients had any major co-existent physical disorder such as hypertension. Patients with history suggestive of other co-morbid psychiatric disorders, such as Panic Disorder, or Alcohol abuse and dependence were also excluded from this study. Subjects were rated onLeyton's Obsessional Inventory (Copper, 1970) and the scores are given in Table 2 . Subjects who had only obsessions and those with obsessions and compulsions were regarded as two separate groups. The duration of illness ranged from 0.6 to 14 years. All patients were drug free for a minimum period of 4 weeks prior to the conduct of this study. None of the patients had a past history of tic disorder or major depression which was not secondary to OCD or had psychotic or endogenous features. There were no clinically significant laboratory findings. All subjects were within 20% of their ideal weight. None of the subjects had a past clinical history of hepatic, renal, endocrinological or cardiovascular illness. None of the female subjects were oh oral contraceptives, but the study was conducted irrespective of the period of their menstrual cycle. There were a total of 72 subjects with OCD who participated in this study.
HEALTHY VOLUNTEERS
Eighteen drug-free healthy controls formed the normal sample for this study. They were recruited from the employees of the institute. Sociodemographic details are given in Table 1 . All of the subjects were studied under similar experimental conditions. None of the subject had any coexistent or past history of psychiatric illness. All were free of major physical illness at the time of conducting this investigation and none had a past history of endocrines, hepatic, renal or cardiovascular disorder. Further there was no historical evidence of psychiatric morbidity in their first degree relatives. 
PROCEDURE
All tests were conducted between 9 and 10 a.m. after an overnight fast. Clonidine hydrochloride, in a dose of 2 microgram/Kg body weight was diluted in 10 cc of normal saline and slowly infused, through a heparin locked i.v. catheter. Clotted blood for hormone assay was collected at 0,15,30 and 60 minutes. Some subject experienced transient drowsiness during the study, but no other side effect was reported.
Details of hormone kit characteristics, with regard to intra and inter-assay coefficient of variation and the sensitivity are given in table 2. Growth hormone (GH) concentration were determined by means of a double antibody radio-immuno assay technique by kits obtained from Bhabha Atomic Research Centre, Bombay. Cortisol concentrations were determined by a single antibody radio-immunoassay technique using kits obtained from Leeco Diagnostics, Michigan, USA. Prolactin concentrations were determined by a double antibody radioimmunoassay technique with kits obtained from Leeco Diagnostics, Michigan, USA. ACTH concentrations were also determined by a double antibody radio-immuno assay technique using kits obtained from Diagnostics Products Corporation, Los Angeles, USA. All assays involving samples from the same subjects were simultaneously performed in duplicate. 
RESULTS
There was significant blunting of the growth hormone response to clonidine when the whole OCD group was considered (Table 3, Figure 1 ), but there was no statistically significant baseline difference. Subsequently subjects were divided into those whose growth hormone response was more than 10 ng/mt (Augmenters) and less than 5 ng/ml (Blunted response).The intermediate group was regarded as having .response similar to controls (no response) as shown in Table 4 . There was a significant excess of blunted response in pure obsessional and augmented response in compulsive subjects.
There was no significant differences in the prolactin response between normal and OCD subjects (Table 5, Fig. 2 ). The Cortisol response was significantly less in all OCD groups as compared to normals (Table 6, Fig.  3 ). The ACTH response was significantly lowerd for the pure obsessional group although this trend was observed for all OCD subjects (Table 7, Fig. 4) . There was no significant cor-* relation between scores in Leyton's Obsessional Inventory and baseline and delta-max hormone values.
On ANOVA, there was significant group differences betweeen OCD and normals for growth hormone, Cortisol and ACTH. Time differences were significant only for growth hormone and ACTH. Two way ANOVA showed that there were significant differences for growth hormone, Cortisol and ACTH (Table  8) .
When pure obsessionals were compared with compulsives (Table 9 ) groups, time and interactional differences were observed mainly for ACTH. 
DISCUSSION
As has been discussed in the introduction, there is very strong evidence which implicates serotonergic dysfunction in OCD. Although it was initially thought that it is the 5HTIB receptor which undergoes behavioural upregalation (Zohar et al., 1987) this was later believed to be the 5HTic receptor since the former was not identified in the human brain (Kahn and Wetzler, 1991) . There however continues to be controversy regarding the exact receptor mechanism of action of mCPP in the human brain (Kahn and Wetzler, 1991) , and the maximum which can be stated that some 5 HT et al., 1990 ).
Neverthless the current study documents noradrenergic dysfunction in OCD. When taken as a whole it appears that there is noradrenergic down-regulation in OCD, as initially reported (Siever et al., 1983) . Nevetheless when the OCD group is subdivided with a relatively large frame it becomes obvious that such a generalisation is sweeping and that there exists noradrenergic heterogeniety in OCD. This explains the observation of a normal to augmented growth hormone response to OCD observed by Hollander (1989) . What is perhaps most interesting is the observation that pure obsessionals tend to have a more down regulated noradrenergic system as compared to the compulsives.
When Zohar et al. (1987 Zohar et al. ( , 1988 administered m-chlorophenylpiperazine to OCD subjects they used to try and stimulate the environment in which such obsessions occur. However it is well recognised that such a situation could be stressful and lead to noradrenergic stimunlation. When Khanna et al. (1989) repeated this study without invoking such stressful environments they were not able to observe exacerbations in obsessive-compulsive psychopathology. Even when this agent is given intravenously the same observation is made (Charney et al., 1988) . It therefore seems reasonable to presume that a 5HT hypersensitive state is a precondition for the development of the OCD, but it on its own may not be sufficient. What is perhaps required in addition either a state wherein exogenously produced stress causes noradrenergic release, or there needs to be an endogenous noradrenergic state which produces such psychopathology (Fig. S) .
The interesting differentiation between obsessionals and compulsives assume great therapeutic importance, as behavioural lines of management are far more successful for compulsive (Marks, 1987) than for pure obsessionals. Perhaps these later subjects require correction of their noradrenergic state to facilitate clinical recovery.
At a methodological plane, it appears from this investigation that the ACTH response to clonidine is a fairly sensitive marker of noradrenergic function. However it is obvious that a study on OCD, in which noradrenergic dysfunction is only now being proposed, would not be sufficient to support this. Nevertheless the rapid rise in ACTH after clonidine administration makes it an important marker for such an approach. This study aims to integrate the serotonergic biology of OCD with noradrenergic dysfunction which can be produced by a host of conditions, such as stress. It may well help in linking behavioural and biiological approaches to the undertaking of OCD and its subsequent therapy. However it would be perhaps too early and too simplistic to accept this model as being final. It needs replication and a greater understanding of the differentiation of pure obsessionals and compulsives. It does not rule out the possibility of involvement of other neurotransmitters and behavioural models, but aims at opening the horizon regarding the undertaking of the very personally distressful obsessive compulsive state. 
